8-KShareholder MattersCorporate ChangesExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Bylaw Amendment (May 21, 2024)

Filed May 21, 2024For Securities:DGX

Summary

Quest Diagnostics Inc. (DGX) filed an 8-K on May 21, 2024, reporting on outcomes from its Annual Meeting of Stockholders held on May 16, 2024. Key among these outcomes is the approval by stockholders of an amendment to the Company's Restated Certificate of Incorporation. This amendment allows for the exculpation of officers, a measure permitted by Delaware law, designed to shield officers from personal liability for certain breaches of fiduciary duty. This change was officially filed with the Secretary of State of Delaware on May 20, 2024. Additionally, the filing details the voting results for director elections, executive compensation approval, and the ratification of PricewaterhouseCoopers as the independent auditor. While director elections and auditor ratification passed with strong support, the advisory vote on executive compensation was also approved. Notably, a stockholder proposal concerning climate risk management was not approved, indicating differing views on the urgency or approach to setting science-based targets and transition planning.

Key Highlights

  • 1Stockholders approved an amendment to the Company's Restated Certificate of Incorporation to provide for the exculpation of officers, effective May 20, 2024.
  • 2All nominated directors were elected for terms expiring at the 2025 Annual Meeting of Stockholders with substantial majority support.
  • 3The advisory resolution to approve executive officer compensation was approved by stockholders.
  • 4PricewaterhouseCoopers was ratified as the Company's independent registered public accounting firm for 2024 with a strong majority vote.
  • 5A stockholder proposal related to managing climate risk through science-based targets and transition planning was not approved.
  • 6The amendment for officer exculpation was approved by a significant margin, reflecting board and shareholder support for protecting executive officers within legal bounds.

Frequently Asked Questions

The primary purpose of the amendment is to provide exculpation for officers, meaning it will shield them from personal liability for breaches of fiduciary duty, as permitted by Delaware law. This is intended to protect officers from certain types of lawsuits, encouraging them to act in the best interests of the company without undue personal risk.

Yes, all nominated directors were elected to the board for terms expiring at the 2025 Annual Meeting of Stockholders. The voting results show strong support for each nominee, with votes 'For' significantly outweighing votes 'Against,' 'Abstain,' and 'Broker Non-Vote.'

The advisory resolution to approve the executive officer compensation disclosed in the Company's 2024 Proxy Statement was approved by stockholders. This is often referred to as a 'say-on-pay' vote, and while advisory, it provides feedback on shareholder sentiment regarding executive pay practices.

The stockholder proposal requesting that Quest Diagnostics manage climate risk through science-based targets and transition planning was not approved by the majority of stockholders. The voting results indicate that more shareholders voted against the proposal than for it.